Kiadis Pharma is a clinical-stage biopharmaceutical company based in Amsterdam developing cell-based therapies for blood cancers. Its lead candidate, ATIR™, is a cell-based product currently in a Phase II international multicenter study intended to confirm and extend prior Phase I/II results. The company will receive an innovation credit to support the Phase II clinical development of ATIR™. Kiadis collaborates with internationally renowned centers in Europe and North America for development and manufacturing of ATIR™. The company is led by Manfred Ruediger, PhD, and is backed by international investors including LSP, Alta Partners, DFJ Esprit, Quest for Growth, MedSciences Capital and NOM. Kiadis Pharma is a clinical-stage biopharmaceutical company developing innovative therapies for patients with late-stage blood cancers and related disorders. Its lead product, ATIR™, is a cell-based medicinal candidate that enables haploidentical stem cell transplantation by selectively eliminating T cells that would cause graft-versus-host disease. In a Phase I/II study ATIR™ demonstrated safety and proof of concept with absence of grade III/IV GvHD, reduced rates of infection, reduced transplant-related mortality, and improved overall survival. ATIR™ has been granted Orphan Drug Designation in both the EU and the USA, with a combined primary market potential cited at more than EUR 1 billion per year. The company collaborates with clinical centers in Europe, Canada and the United States and is based in Amsterdam, The Netherlands. The recent financing will support a confirmatory multi-center Phase II proof-of-concept study and preparation of a pivotal Phase II/III study.

Total raised

$17M

Funding rounds

2

Latest round

Grant

Latest activity

Jun 2013